

# **Interview with Dr. Jaquelyn McCandless: Low Dose Naltrexone, (LDN) past study, prospective study**

**Jaquelyn McCandless, MD and Teri Arranga<sup>b</sup>**

<sup>a</sup>Email: [jmccandless@prodigy.net](mailto:jmccandless@prodigy.net)

<sup>b</sup>AutismOne Radio

1816 Houston Ave.

Fullerton, CA 92833 USA

Email: [tarranga@autismone.org](mailto:tarranga@autismone.org)

Website: [www.autismone.org](http://www.autismone.org)

---

## **Abstract**

Naltrexone is a generic, FDA approved opioid antagonist that when used in ultra-tiny doses (less than 1/10<sup>th</sup> the ordinary dose) acts as an immune modulator/enhancer to optimize the immune functioning of those who are immune-compromised, as autistic persons are known to be. It also operates as a neurohumoral agent that has effects on cognition, socialization, and language. Naltrexone must be compounded to obtain ultra tiny doses, called low dose naltrexone (LDN) and can be made into a cream for children or small capsules for adults, to be used one time daily at bedtime. It is non-toxic, non-invasive, effective, and inexpensive. A recent study at Penn State on Crohn's Disease has shown it to be effective and safe; a second study on Crohn's at Penn has just been approved; a study at UCSC on LDN is starting on multiple sclerosis and one at Stanford on fibromyalgia. A study on autistic children has been approved in Israel; a study on HIV+ persons in Africa to show the effectiveness of LDN to prevent progression to full-blown AIDS is being proposed. In this interview Dr. McCandless discusses LDN and the results of the use of this agent in her autism practice and in her informal study of autistic children and their parents.

© Copyright 2006 Pearblossom Private School, Inc.–Publishing Divison. All rights reserved.

*Keywords:* Low-Dose Naltrexone (LDN), endorphins, autism, HIV+AIDS, autoimmunity, immunomodulation, CD4+